Table 4. Hazard Ratio (95%CI) of CVD endpoints and all-cause mortality among participants with impaired fasting glucose (2 definitions) relative to normoglycaemia.

		No diabetes with FPG ≤6.0mmol/L N=6352	Impaired fasting glucose: NCEP ATPIII (FPG 6.1-6.9mmol/L); N=95		No diabetes with FPG ≤5.5mmol/L N=6144	Impaired fasting glycaemia: ADA (FPG 5.6-6.9mmol/L); N=303
CVD events			HR (95%CI)			HR (95%CI)
	Events (%)	2341 (36.9)	40 (42.1)		2268 (36.9)	113 (37.3)
	Model l	1.0	1.25	(0.92-1.71)	1.0	1.05	(0.87-1.27)
	Model 2	1.0	1.14	(0.83-1.55)	1.0	0.95	(0.78-1.15)
CHD events
	Events (%)	1448 (22.8)	26 (27.4)		1402 (22.8)	72 (23.8)
	Model 1	1.0	1.27	(0.86-1.87)	1.0	1.07	(0.84-1.36)
	Model 2	1.0	1.09	(0.74-1.61)	1.0	0.93	(0.73-1.18)
Stroke
	Events (%)	397 (6.2)	8 (8.4)		381 (6.2)	24 (7.9)
	Model 1	1.0	1.39	(0.69-2.81)	1.0	1.29	(0.85-1.94)
	Model 2	1.0	1.25	(0.62-2.53)	1.0	1.17	(0.77-1.78)
CHD death
	Events (%)	353 (5.6)	8 (8.4)		342 (5.6)	19 (6.3)
	Model 1	1.0	1.55	(0.77-3.12)	1.0	1.12	(0.71-1.78)
	Model 2	1.0	1.34	(0.66-2.72)	1.0	1.00	(0.62-1.59)
All-cause mortality	Events (%)	1224 (19.3)	20 (21.1)		1181 (19.2)	63 (20.8)
	Model 1	1.0	1.12	(0.72-1.75)	1.0	1.08	(0.84-1.39)
	Model 2	1.0	1.02	(0.66-1.60)	1.0	1.01	(0.79-1.31)

Model 1: Adjusted for randomised treatment and age.

Model 2: In addition adjusted for BP, hypertension, cholesterol (HDL & LDL), triglycerides, nitrates use, history of angina, social deprivation score (DEPCAT), various medications (aspirin, ACE inhibitors, B-blockers, calcium channel blockers, diuretics, other)

FPG: fasting plasma glucose; Q: quintile; HR: hazard ratio; CI: confidence interval; CVD: cardiovascular disease; CHD: coronary heart disease. Multiply by 18 to convert glucose from mmol/L to mg/dL.